TME Pharma: positive results in brain tumors
According to the company, five out of six patients treated with a combination therapy combining its NOX-A12, radiotherapy and Roche's Avastin, were alive at the end of the 15-month trial.
For reference, the expected median overall survival for patients under current standards of care, with tumors refractory to chemotherapy and whose tumors remain detectable after surgery, is around 10 months.
'As long as treatment or follow-up of these patients is ongoing, median overall survival (mOS) will continue to improve', adds the biotech.
Glioblastoma, considered to be the most serious type of brain tumor, is increasingly common in the elderly as the population ages.
From TME's point of view, this combination could therefore offer a 'clinically significant' improvement over current standards in this difficult, extremely critical prognosis indication.
The company believes that it is in the process of establishing an 'attractive' clinical profile for its lead compound, with a view to setting up a possible partnership and future discussions with regulatory authorities concerning future market access.
Following these announcements, AB Science shares gained almost 4% on Tuesday morning on the Paris Bourse, in a market itself up 0.6%.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction